【全非资讯·尼日利亚】 尼日利亚向保护数百万儿童免受疟疾侵害迈出新步伐

aipl1234

#尼日利亚 #西非 #非洲

常年疟疾化学预防效果研究的第一阶段已为尼日利亚提供了强有力的本地证据，以指导国家政策。\n\n2026年8月5日，政府领导人、研究人员和发展伙伴齐聚阿布贾，参加常年疟疾化学预防（PMC）效果研究的国家成果发布会。此次会议标志着尼日利亚在采纳一项能够保护儿童度过最脆弱时期的全新干预措施的道路上迈出了关键一步。该研究的成功完成为尼日利亚提供了指导国家政策的坚实本地证据。\n\n该研究生成了令人信服的证据，表明PMC可以显着减少两岁以下儿童的疟疾发病率，同时能够通过尼日利亚现有的初级卫生保健系统进行有效分发。这些结果增强了决策者和合作伙伴对PMC能够成为该国综合疟疾预防方案重要补充的信心。\n\n疟疾防治国际组织（Malaria Consortium）实施高级技术顾问Dr Oslusola Oresanya表示：这是一个重要的里程碑，体现了国家在抗击疟疾斗争中对基于证据的创新的持续承诺。我们很荣幸支持联邦政府实施能够保护数百万尼日利亚人免受疟疾和其他可预防疾病侵害的项目。\n\n在2023年至2025年于Osun州进行的研究第一阶段中，接受PMC的儿童确诊疟疾病例减少了 22%，因病前往医疗机构的总就诊次数下降了 19%。服用用于治疗疟疾的联合药物乙胺嘧啶-磺胺多辛（SP）的儿童，在服药后28天内获得了超过50%的抗疟疾感染保护。当PMC与\n\n除了有效性之外，该研究还证实，幼儿每月重复服用SP是安全的，没有发生严重的不良药物反应。成本和运营分析还表明，通过现有的常规免疫服务分发PMC是经济实惠的，并且可以在不建立平行分发系统的情况下进行整合。\n\n这些发现对尼日利亚未来的预防工作尤为鼓舞人心。数学模型表明，在2026年至2030年期间，在尼日利亚南部的符合条件地区全面推广PMC，可以将2至18个月儿童的临床疟疾病例减少20%至35%，从而避免数万起疟疾病例并显著提高儿童生存率。

中文导读

跟上WhatsApp上的最新头条| LinkedIn



原文原文 / Original Text

The first phase of the Perennial Malaria Chemoprevention Effect study has provided Nigeria with robust local evidence to guide national policy.

On 5 August 2026, government leaders, researchers and development partners gathered in Abuja for the national dissemination meeting of the Perennial Malaria Chemoprevention (PMC) Effect study. The meeting marked a pivotal moment in Nigeria's journey towards adopting a new intervention capable of protecting children during their most vulnerable years. The successful completion of the study has provided Nigeria with robust local evidence to guide national policy.

The study has generated compelling evidence that PMC can significantly reduce malaria among children under two years of age while being delivered effectively through Nigeria's existing primary healthcare system. These results have strengthened confidence among policymakers and partners that PMC can become an important addition to the country's comprehensive malaria prevention package.

"This is an important milestone that reflects the country's continued commitment to evidence-based innovation in the fight against malaria. We are proud to support the Federal Government in implementing programmes that protect millions of Nigerians from malaria and other preventable diseases," said Dr Oslusola Oresanya, Senior Technical Advisor - Implementation at Malaria Consortium.

Keep up with the latest headlines on WhatsApp | LinkedIn

In the first phase of the study in Osun state between 2023 and 2025, children who received PMC experienced a 22 percent reduction in confirmed malaria cases, while overall health facility visits for illness fell by 19 percent. Those who received sulfadoxine-pyrimethamine (SP) -- a combination medication used to treat malaria -- benefited from more than 50 percent protection against malaria infection within 28 days of taking SP. Even greater protection was observed when PMC was combined with the

Beyond its effectiveness, the study confirmed that repeated monthly doses of SP are safe for young children, with no serious adverse drug reactions. Cost and operational analyses also showed that delivering PMC through existing routine immunisation services is affordable and can be integrated without creating parallel delivery systems.

These findings are especially encouraging for the future of prevention efforts in Nigeria. Mathematical modelling indicates that scaling up PMC across eligible areas in southern Nigeria between 2026 and 2030 could reduce clinical malaria cases among children aged 2-18 months by 20 to 35 percent, preventing tens of thousands of malaria episodes and significantly improving child survival.

本文为英文资讯，中文内容由机器翻译生成，仅供参考。详情请阅读文末原文。

—— 资讯转载说明 ——
本文由非洲论坛根据公开信息整理，供中国读者查阅，不代表本站立场。
来源：AllAfrica (https://allafrica.com/)
原文链接：https://allafrica.com/stories/202608130377.html
转载请遵守原发布方版权与引用规定。